Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer

24 Oct 2022

Abstract excerpt

Cancer immunotherapy including immune checkpoint inhibitors (ICI) has revolutionized non-small cell lung cancer (NSCLC) therapy. Recently, the microbiota status “before” initiation of ICI therapy has been emphasized as a predictive biomarker in patients undergoing ICI therapy. However, the microbiota diversity and composition “during” ICI therapy is unknown. This multicenter, prospective observational study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Gut microbiota and health
Share to Mycobacterium research and diagnosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36353732
DOI: 10.3389/fmolb.2022.1040424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancerPMID 36353732Read ↗

Gut Microbiome Diversity and Specific Composition During Immunotherapy in Japanese Responders with Non-Small Cell Lung CancerSemantic proximity Read ↗

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut MicrobiotaSemantic proximity Read ↗

Specific gut microbiome signature predicts the early-stage lung cancerSemantic proximity Read ↗

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitSemantic proximity Read ↗

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Salivary Microbial Signature Highlighting Actinomyces as a Predictor of Immune-Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer.Semantic proximity Read ↗

Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohortSemantic proximity Read ↗

Human Microbiome as Clinical Biomarkers for Respiratory Tract CancersSemantic proximity Read ↗

Gut Microbiota in Lung Cancer: Where Do We Stand?Semantic proximity Read ↗

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read ↗

Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-small Cell Lung CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.